Table 1.

Proportion of subjects with detectable anti-HPV, ≥3 LU and ≥10 LU anti-HPV and GMTs in 2 study groups pre- and post-booster administration

	Group qHPV pre-booster				Group bHPV pre-booster				Group qHPV 1 month post-booster				Group bHPV 1 month post-booster
	N = 181				N = 182				N = 181				N = 182
Results	% ≥1 LU	% ≥3 LU	% ≥10 LU	GMT 95%CI	% ≥1 LU	% ≥3 LU	% ≥10 LU	GMT 95%CI	% ≥1 LU	% ≥3 LU	% ≥10 LU	GMT 95%CI	% ≥1 LU	% ≥3 LU	% ≥10 LU	GMT 95%CI
HPV 6	100	100	96	82	100	99	94	81	100	100	100	1666	100	100	99	127
				70–95				68–96				1506–1844				112–145
HPV 11	100	100	100	312	100	100	100	332	100	100	100	4419	100	100	100	474
				271–359				289–382				4064–4805				421–534
HPV 16	100	100	100	322	100	100	99	289	100	100	100	4536	100	100	100	5458
				278–374				246–340				4168–4937				4989–5971
HPV 18	99	97	89	50	99	98	91	54	100	100	100	1710	100	100	100	2665
				42–61				44–65				1523–1919				2364–3006